MA41562B1 - Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires - Google Patents
Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculairesInfo
- Publication number
- MA41562B1 MA41562B1 MA41562A MA41562A MA41562B1 MA 41562 B1 MA41562 B1 MA 41562B1 MA 41562 A MA41562 A MA 41562A MA 41562 A MA41562 A MA 41562A MA 41562 B1 MA41562 B1 MA 41562B1
- Authority
- MA
- Morocco
- Prior art keywords
- agonists
- heteroaryl
- pyridine
- hydroxy
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne des composés de formule (i), dans laquelle a, x et y sont tels que définis dans la spécification, et des compositions comprenant l'un quelconque de ces nouveaux composés. Ces composés sont des agonistes d'apj qui peuvent être utilisés en tant que médicaments.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562170215P | 2015-06-03 | 2015-06-03 | |
PCT/US2016/035482 WO2016196771A1 (fr) | 2015-06-03 | 2016-06-02 | Agonistes d'apj 4-hydroxy-3-(hétéroaryl)pyridine-2-one à utiliser dans le traitement de troubles cardio-vasculaires |
Publications (2)
Publication Number | Publication Date |
---|---|
MA41562A1 MA41562A1 (fr) | 2018-05-31 |
MA41562B1 true MA41562B1 (fr) | 2019-05-31 |
Family
ID=56131647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA41562A MA41562B1 (fr) | 2015-06-03 | 2016-06-02 | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires |
Country Status (35)
Country | Link |
---|---|
US (3) | US10011594B2 (fr) |
EP (2) | EP3303330B1 (fr) |
JP (2) | JP6483288B2 (fr) |
KR (1) | KR102066336B1 (fr) |
CN (1) | CN107922401B (fr) |
AR (1) | AR104884A1 (fr) |
AU (1) | AU2016270903B2 (fr) |
CA (1) | CA2988147C (fr) |
CL (1) | CL2017003055A1 (fr) |
CO (1) | CO2017013229A2 (fr) |
CY (1) | CY1121938T1 (fr) |
DK (1) | DK3303330T3 (fr) |
EA (1) | EA034912B1 (fr) |
ES (1) | ES2739526T3 (fr) |
HK (1) | HK1247915B (fr) |
HR (1) | HRP20191327T1 (fr) |
HU (1) | HUE045546T2 (fr) |
IL (1) | IL255951B (fr) |
LT (1) | LT3303330T (fr) |
MA (1) | MA41562B1 (fr) |
ME (1) | ME03474B (fr) |
MX (1) | MX2017014956A (fr) |
MY (1) | MY189453A (fr) |
NZ (1) | NZ738563A (fr) |
PE (1) | PE20180506A1 (fr) |
PH (1) | PH12017502158A1 (fr) |
PL (1) | PL3303330T3 (fr) |
PT (1) | PT3303330T (fr) |
RS (1) | RS59220B1 (fr) |
SI (1) | SI3303330T1 (fr) |
TN (1) | TN2017000503A1 (fr) |
TW (1) | TWI672299B (fr) |
UY (1) | UY36705A (fr) |
WO (1) | WO2016196771A1 (fr) |
ZA (1) | ZA201708191B (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9573936B2 (en) | 2015-05-20 | 2017-02-21 | Amgen Inc. | Triazole agonists of the APJ receptor |
MX2017014956A (es) | 2015-06-03 | 2018-04-13 | Squibb Bristol Myers Co | Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares. |
JP6837482B2 (ja) | 2015-10-14 | 2021-03-03 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Apjアゴニストとしての2,4−ジヒドロキシ−ニコチンアミド |
EA037257B1 (ru) | 2015-12-04 | 2021-02-26 | Бристол-Маерс Сквибб Компани | Новые агонисты рецептора апелина и способы применения |
ES2854733T3 (es) * | 2015-12-16 | 2021-09-22 | Bristol Myers Squibb Co | Heteroarilhidroxipirimidinonas como agonistas del receptor APJ |
EP3433247B1 (fr) * | 2016-03-24 | 2021-09-08 | Bristol-Myers Squibb Company | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj |
US9988369B2 (en) | 2016-05-03 | 2018-06-05 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the APJ receptor |
CN109641843B (zh) | 2016-06-14 | 2022-07-19 | 百时美施贵宝公司 | 作为apj激动剂的4-羟基-3-磺酰基吡啶-2(1h)-酮 |
JP6993357B2 (ja) | 2016-06-14 | 2022-01-13 | ブリストル-マイヤーズ スクイブ カンパニー | Apjアゴニストとしての6-ヒドロキシ-5-(フェニル/ヘテロアリールスルホニル)ピリミジン-4(1h)-オン |
WO2018071622A1 (fr) * | 2016-10-14 | 2018-04-19 | Bristol-Myers Squibb Company | Agonistes d'apj de 3-sulfonyl-5-aminopyridine -2,4-diol |
EP3541804A1 (fr) | 2016-11-16 | 2019-09-25 | Amgen Inc. | Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj |
WO2018093579A1 (fr) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Composés phényle triazole en tant qu'agonistes du récepteur apj |
EP3541805B1 (fr) | 2016-11-16 | 2020-10-14 | Amgen Inc. | Triazoles substitués par hétéroaryle utilisés en tant qu'agonistes du récepteur apj |
WO2018097944A1 (fr) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Composés de triazole furane utilisés en tant qu'agonistes du récepteur apj |
MA46824A (fr) | 2016-11-16 | 2019-09-25 | Amgen Inc | Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj |
WO2018093580A1 (fr) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Composés de triazole pyridyle en tant qu'agonistes du récepteur apj |
US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
EP3704122B1 (fr) | 2017-11-03 | 2021-09-01 | Amgen Inc. | Agonistes de triazole fusionnés du récepteur apj |
WO2019213006A1 (fr) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Pyrimidinones substituées en tant qu'agonistes du récepteur apj |
CN109704981B (zh) * | 2019-02-16 | 2022-01-28 | 安徽诺全药业有限公司 | 取代合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法 |
CN109704980B (zh) * | 2019-02-16 | 2022-05-13 | 安徽大学 | 一种(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的制备方法 |
CN109734616B (zh) * | 2019-02-16 | 2022-05-13 | 安徽诺全药业有限公司 | 两步法合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1001159A (en) | 1910-07-25 | 1911-08-22 | Elizabeth Nielsen | Skirt-gage. |
GB1472257A (en) | 1973-09-10 | 1977-05-04 | Christiaens Sa A | Derivative of 4-hydroxy-5-azacoumarin |
US4866182A (en) | 1988-02-18 | 1989-09-12 | Merrell Dow Pharmaceuticals Inc. | Cardiotonic alkanoyl and aroyl oxazolones |
US5338740A (en) | 1993-07-13 | 1994-08-16 | Pfizer Inc. | Angiotensin II receptor antagonists |
JP3795305B2 (ja) | 1999-07-19 | 2006-07-12 | 田辺製薬株式会社 | 医薬組成物 |
PT1379525E (pt) | 2001-02-21 | 2007-12-04 | Astrazeneca Ab | Compostos heteropolicíclicos e sua utilização como antagonistas dos receptores metabotrópicos de glutamato |
HUP0303624A3 (en) | 2001-03-28 | 2005-06-28 | Pfizer | N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad and process for preparation of the compounds |
WO2003020719A1 (fr) | 2001-09-03 | 2003-03-13 | Takeda Chemical Industries, Ltd. | Derives de 1,3-benzothiazinone et leur utilisation |
JP2005162612A (ja) | 2002-01-09 | 2005-06-23 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
JP2005170790A (ja) | 2002-01-09 | 2005-06-30 | Ajinomoto Co Inc | N−アルキルスルフォニル置換アミド誘導体 |
ES2334990T3 (es) * | 2002-02-14 | 2010-03-18 | Pharmacia Corporation | Piridinonas sustituidas como moduladores de p38 map quinasa. |
US20040147561A1 (en) * | 2002-12-27 | 2004-07-29 | Wenge Zhong | Pyrid-2-one derivatives and methods of use |
WO2005004818A2 (fr) | 2003-07-09 | 2005-01-20 | Imclone Systems Incorporated | Composes heterocycliques et leur utilisation comme agents anticancereux |
US20060004001A1 (en) | 2004-02-27 | 2006-01-05 | Merz Pharma Gmbh & Co., Kgaa | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors |
PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
MXPA06011167A (es) | 2004-04-01 | 2007-01-25 | Eli Lilli And Company | Agentes del receptor h3 de histamina, preparacion y usos terapeuticos. |
AU2005257999B2 (en) | 2004-06-18 | 2011-12-08 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
DE602005014786D1 (de) | 2004-07-26 | 2009-07-16 | Lilly Co Eli | Oxazolderivate als histamin-h3-rezeptor-wirkstoffe, deren herstellung und therapeutische verwendung |
EP1655283A1 (fr) | 2004-11-08 | 2006-05-10 | Evotec OAI AG | Inhibiteurs de 11béta-HSD1 |
WO2006123165A2 (fr) * | 2005-05-19 | 2006-11-23 | Astex Therapeutics Limited | Composes pharmaceutiques |
WO2007023242A1 (fr) | 2005-08-24 | 2007-03-01 | Merz Pharma Gmbh & Co. Kgaa | Tétrahydroquinolinones et leur usage en tant que modulateurs des récepteurs de glutamate métabotropiques |
EP1984353B1 (fr) | 2006-01-23 | 2015-12-30 | Amgen, Inc | Modulateurs de la kinase de l aurore et procede d utilisation |
JP2007314516A (ja) | 2006-04-25 | 2007-12-06 | Daiichi Sankyo Co Ltd | 2以上の置換基を有するベンゼン化合物を含有する医薬 |
WO2008016968A2 (fr) | 2006-08-03 | 2008-02-07 | Trustees Of Tufts College | Analogues de la niacine sans effets de bouffées congestives et procédés d'utilisation |
WO2008019090A2 (fr) | 2006-08-04 | 2008-02-14 | Praecis Pharmaceuticals Incorporated | Composés chimiques |
EP1894924A1 (fr) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Composés hétérocycliques de liason du FXR |
JP2010511629A (ja) | 2006-12-01 | 2010-04-15 | ノバルティス アーゲー | 生理的心肥大の促進のためのプロテインチロシンホスファターゼ阻害剤 |
US20100152210A1 (en) | 2007-03-28 | 2010-06-17 | Neuro Search A/S/ | Purinyl derivatives and their use as potassium channel modulators |
EP2674417A3 (fr) * | 2007-11-21 | 2014-04-09 | Decode Genetics EHF | Inhibiteurs de pde4 biaryle pour le traitement de l'inflammation |
JP2011510067A (ja) | 2008-01-25 | 2011-03-31 | トレント・ファーマシューティカルズ・リミテッド | 組合せ医薬品 |
TW201000107A (en) | 2008-04-09 | 2010-01-01 | Infinity Pharmaceuticals Inc | Inhibitors of fatty acid amide hydrolase |
AU2009253046A1 (en) | 2008-05-30 | 2009-12-03 | Foster Wheeler Energia Oy | Method of and system for generating power by oxyfuel combustion |
MX2011000150A (es) | 2008-06-30 | 2011-04-05 | Cylene Pharmaceuticals Inc | Compuestos de oxoindol. |
JP5535931B2 (ja) | 2008-10-27 | 2014-07-02 | 武田薬品工業株式会社 | 二環性化合物 |
NZ592738A (en) * | 2008-11-04 | 2013-01-25 | Anchor Therapeutics Inc | APJ receptor compounds attached to a lipophilic tether through a carbonyl linker |
RU2012116207A (ru) | 2009-09-24 | 2013-10-27 | Ф.Хоффманн-Ля Рош Аг | Производные индола в качестве модуляторов crac |
CN102510864A (zh) | 2009-09-24 | 2012-06-20 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒杂环化合物 |
WO2011062955A2 (fr) | 2009-11-18 | 2011-05-26 | University Of Massachusetts | Composés pour la modulation de tlr2 |
US8609866B2 (en) | 2009-12-18 | 2013-12-17 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
CN102241621A (zh) | 2010-05-11 | 2011-11-16 | 江苏恒瑞医药股份有限公司 | 5,5-双取代-2-亚氨基吡咯烷类衍生物、其制备方法及其在医药上的应用 |
EP2578573A4 (fr) | 2010-05-24 | 2014-08-06 | Toa Eiyo Ltd | Dérivé d'imidazole condensé |
WO2012040532A1 (fr) * | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Composés oxadiazoles substitués et leur utilisation en tant qu'agonistes du s1p1 |
WO2012074022A1 (fr) | 2010-12-01 | 2012-06-07 | 旭硝子株式会社 | Complexe cationique d'iridium et composition émettant de la lumière |
CA2831978A1 (fr) | 2011-03-03 | 2012-09-07 | Universitat Des Saarlandes | Derives biaryle en tant qu'inhibiteurs selectifs de la 17beta-hydroxysteroide deshydrogenase de type 2 |
EP2697196A1 (fr) | 2011-04-13 | 2014-02-19 | Activesite Pharmaceuticals, Inc. | Promédicaments d'inhibiteurs de la kallicréine plasmatique |
EP2709609B1 (fr) | 2011-05-17 | 2017-10-04 | Shionogi & Co., Ltd. | Composés hétérocycliques |
ES2727479T3 (es) | 2011-12-23 | 2019-10-16 | Basf Se | Compuestos de isotiazolina para combatir plagas de invertebrados |
CA2871270A1 (fr) * | 2012-05-02 | 2013-11-07 | Lupin Limited | Composes substitues de pyridine en tant que modulateurs de crac |
WO2013167633A1 (fr) | 2012-05-09 | 2013-11-14 | Basf Se | Composés d'acrylamide pour la lutte contre des animaux nuisibles invertébrés |
BR112014030720A8 (pt) | 2012-06-08 | 2021-06-22 | The Us Gov As Represented By The Department Of Veterans Affairs | composto, composição farmacêutica e usos de inibidores de fbx03 |
WO2014006045A1 (fr) | 2012-07-02 | 2014-01-09 | Max-Delbrück-Centrum für Molekulare Medizin | Dérivés du psoralène en prévention ou en traitement de l'insuffisance cardiaque ou de l'hypertrophie cardiaque |
CN103570625A (zh) | 2012-07-19 | 2014-02-12 | 南京英派药业有限公司 | N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用 |
US20140073634A1 (en) | 2012-08-24 | 2014-03-13 | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center | Heterocyclic modulators of hif activity for treatment of disease |
KR20150058284A (ko) * | 2012-09-21 | 2015-05-28 | 사노피 | Apj 수용체 조절자로서의 벤조이미다졸-카르복시산 아미드 유도체 |
US10035790B2 (en) | 2012-10-19 | 2018-07-31 | Exelixis, Inc. | RORγ modulators |
EP2972394A4 (fr) | 2013-03-15 | 2016-11-02 | Sloan Kettering Inst Cancer | Imagerie cardiaque à ciblage hsp90 et traitement associé |
EP3027625B1 (fr) | 2013-07-31 | 2018-05-30 | Merck Sharp & Dohme Corp. | Derives spiro-fusionnes de piperidine utiles dans le traitement, entre autres, de l'hypertension et de l' insuffisance cardiaque aiguë ou chronique |
JP6199197B2 (ja) | 2014-02-07 | 2017-09-20 | 花王株式会社 | ポリオキシアルキレンアルキルエーテルカルボン酸塩の製造方法 |
JP2017071553A (ja) | 2014-02-25 | 2017-04-13 | 味の素株式会社 | ヘテロ原子−メチレン−ヘテロ環構造を有する新規化合物 |
KR20160127138A (ko) | 2014-03-20 | 2016-11-02 | 바이엘 파마 악티엔게젤샤프트 | 신규 화합물 |
JP6552061B2 (ja) | 2014-06-10 | 2019-07-31 | サンフォード−バーンハム メディカル リサーチ インスティテュート | 代謝型グルタミン酸受容体の負のアロステリックモジュレーター(nams)とその使用 |
US9573936B2 (en) | 2015-05-20 | 2017-02-21 | Amgen Inc. | Triazole agonists of the APJ receptor |
MX2017014956A (es) | 2015-06-03 | 2018-04-13 | Squibb Bristol Myers Co | Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares. |
KR101711744B1 (ko) | 2015-07-16 | 2017-03-02 | 경희대학교 산학협력단 | 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층 |
JP6837482B2 (ja) | 2015-10-14 | 2021-03-03 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Apjアゴニストとしての2,4−ジヒドロキシ−ニコチンアミド |
WO2017091513A1 (fr) | 2015-11-24 | 2017-06-01 | Daiichi Sankyo Company, Limited | Nouveaux dérivés azolés comme agoniste du récepteur de l'apéline |
EA037257B1 (ru) | 2015-12-04 | 2021-02-26 | Бристол-Маерс Сквибб Компани | Новые агонисты рецептора апелина и способы применения |
MA43417A (fr) | 2015-12-09 | 2018-10-17 | Res Triangle Inst | Agonistes améliorés du récepteur de l'apéline (apj) et leurs utilisations |
ES2854733T3 (es) | 2015-12-16 | 2021-09-22 | Bristol Myers Squibb Co | Heteroarilhidroxipirimidinonas como agonistas del receptor APJ |
EP3433247B1 (fr) | 2016-03-24 | 2021-09-08 | Bristol-Myers Squibb Company | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj |
CN109641843B (zh) | 2016-06-14 | 2022-07-19 | 百时美施贵宝公司 | 作为apj激动剂的4-羟基-3-磺酰基吡啶-2(1h)-酮 |
JP6993357B2 (ja) | 2016-06-14 | 2022-01-13 | ブリストル-マイヤーズ スクイブ カンパニー | Apjアゴニストとしての6-ヒドロキシ-5-(フェニル/ヘテロアリールスルホニル)ピリミジン-4(1h)-オン |
WO2018071622A1 (fr) | 2016-10-14 | 2018-04-19 | Bristol-Myers Squibb Company | Agonistes d'apj de 3-sulfonyl-5-aminopyridine -2,4-diol |
-
2016
- 2016-06-02 MX MX2017014956A patent/MX2017014956A/es unknown
- 2016-06-02 PE PE2017002482A patent/PE20180506A1/es unknown
- 2016-06-02 UY UY0001036705A patent/UY36705A/es unknown
- 2016-06-02 EP EP16729454.5A patent/EP3303330B1/fr active Active
- 2016-06-02 JP JP2017562603A patent/JP6483288B2/ja active Active
- 2016-06-02 HU HUE16729454A patent/HUE045546T2/hu unknown
- 2016-06-02 TN TNP/2017/000503A patent/TN2017000503A1/en unknown
- 2016-06-02 LT LTEP16729454.5T patent/LT3303330T/lt unknown
- 2016-06-02 PL PL16729454T patent/PL3303330T3/pl unknown
- 2016-06-02 MA MA41562A patent/MA41562B1/fr unknown
- 2016-06-02 EP EP19168724.3A patent/EP3530660A1/fr not_active Withdrawn
- 2016-06-02 CN CN201680045336.7A patent/CN107922401B/zh active Active
- 2016-06-02 KR KR1020177037657A patent/KR102066336B1/ko active IP Right Grant
- 2016-06-02 ES ES16729454T patent/ES2739526T3/es active Active
- 2016-06-02 AU AU2016270903A patent/AU2016270903B2/en active Active
- 2016-06-02 SI SI201630316T patent/SI3303330T1/sl unknown
- 2016-06-02 RS RSP20190961 patent/RS59220B1/sr unknown
- 2016-06-02 ME MEP-2019-211A patent/ME03474B/fr unknown
- 2016-06-02 CA CA2988147A patent/CA2988147C/fr active Active
- 2016-06-02 PT PT16729454T patent/PT3303330T/pt unknown
- 2016-06-02 US US15/171,276 patent/US10011594B2/en active Active
- 2016-06-02 EA EA201792548A patent/EA034912B1/ru not_active IP Right Cessation
- 2016-06-02 NZ NZ73856316A patent/NZ738563A/en unknown
- 2016-06-02 MY MYPI2017704612A patent/MY189453A/en unknown
- 2016-06-02 DK DK16729454.5T patent/DK3303330T3/da active
- 2016-06-02 AR ARP160101639A patent/AR104884A1/es unknown
- 2016-06-02 TW TW105117468A patent/TWI672299B/zh active
- 2016-06-02 WO PCT/US2016/035482 patent/WO2016196771A1/fr active Application Filing
-
2017
- 2017-11-27 IL IL255951A patent/IL255951B/en active IP Right Grant
- 2017-11-28 PH PH12017502158A patent/PH12017502158A1/en unknown
- 2017-11-30 CL CL2017003055A patent/CL2017003055A1/es unknown
- 2017-12-01 ZA ZA2017/08191A patent/ZA201708191B/en unknown
- 2017-12-21 CO CONC2017/0013229A patent/CO2017013229A2/es unknown
-
2018
- 2018-05-29 US US15/990,855 patent/US10336739B2/en active Active
- 2018-06-04 HK HK18107278.8A patent/HK1247915B/zh unknown
-
2019
- 2019-02-13 JP JP2019023478A patent/JP2019094345A/ja active Pending
- 2019-05-14 US US16/411,221 patent/US20190263791A1/en not_active Abandoned
- 2019-07-24 HR HRP20191327 patent/HRP20191327T1/hr unknown
- 2019-07-29 CY CY20191100803T patent/CY1121938T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41562A1 (fr) | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires | |
MA39783A (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
MA42109B1 (fr) | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase | |
MA39554A3 (fr) | Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock | |
MA45020A (fr) | Dérivés sulfonamides aromatiques | |
MA47043A1 (fr) | Composés indole carboxamides utiles comme inhibiteurs de kinase | |
MA35342B1 (fr) | Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase | |
MA42410A (fr) | Oxystérols et leurs méthodes d'utilisation | |
MA38398B1 (fr) | Composés biaryle amides en tant qu'inhibiteurs de kinase | |
MA43409B1 (fr) | Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton | |
MA37762B1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
MA42397B1 (fr) | 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b | |
MA41185B1 (fr) | Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc | |
MA38810B1 (fr) | Inhibiteurs de rorc2 méthodes d'utilisation associées | |
MA39927B1 (fr) | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques | |
MA38410A1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
MA38679A1 (fr) | Modulateurs du récepteur de cxcr7 | |
MA39253A1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
MA39337A1 (fr) | Modulateurs de pyrazines de gpr6 | |
MA39750B1 (fr) | Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2 | |
MA37849A1 (fr) | Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du reflux | |
MA38523A1 (fr) | Composés triazoliques tricycliques utilisés en tant que ligands des récepteurs sigma |